Total Funding
4
Total FundingSeed raised
Growth Score
pts
Heat Score
-52 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Imutex, a startup with a Phase IIa-ready universal flu vaccine.
- Kimbell Duncan: Director
- Cathal Friel: DirectorPast Role: Amryt Pharma, Co-Founder and Director
About the Company
Imutex Limited, formed in 2016, is a joint venture between SEEK Group and hVIVO plc to accelerate the development of a Broad-Spectrum Influenza Vaccine (BIV) and a Zika Vaccine.
The development of BIV and Zika vaccines are key public health priorities identified by the Centers for Disease Control and Prevention (CDC) and the National Institutes
of Health (NIH) in the United States.
